Notably, the anti-tumor efficacy of HB0025 was stronger at the equivalent molar dose than that of the combination of single functional antibodies HB0023 and HB002.1T (p < 0.05) (Figure 3A, Supplementary Figure 1 and Supplementary Table 3) and the combination treatment of anti-PD-L1 antibody atezolizumab and anti-VEGF antibody bevacizumab on the market (p < 0.05) (Figure 3B). This evidence concerns the gene CD274 and neoplasm.